Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.
NCT ID: NCT03878433
Last Updated: 2021-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2019-04-01
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.
NCT03941808
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma
NCT06278948
Randomized Study Using SM-030 Gel for Adults With Melasma
NCT06454747
Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins
NCT06253468
Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser
NCT00863278
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug
Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
Glisodin
500 mg/day between 12 weeks
No Drug
2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
placebo
Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glisodin
500 mg/day between 12 weeks
placebo
Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed inform consent
Exclusion Criteria
* Other pigmentary disorder of the afce
* Use of depigmentant agent in the month before the inclusion
* Use of topical steroid, tretinoin, hydroquinone in the month before the inclusion
* Coeliac disease or allergy to gluten
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Passeron Thierry, PhD
Role: PRINCIPAL_INVESTIGATOR
Dermatologie, CHU de Nice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nice - Dermatology
Nice, Alpes-Maritime, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-PP-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.